Anaconda Biomed S.L., based in Barcelona, is a pioneering medical device startup co-founded by Dr. Marc Ribo and Dr. Ofir Arad. The company specializes in developing advanced catheters designed to perform mechanical thrombectomies safely and efficiently. Mechanical thrombectomy is a procedure used to remove blood clots from arteries in the brain, which is crucial in treating strokes. Strokes are the leading cause of permanent disability globally, imposing a significant financial burden on national health systems, amounting to billions of dollars annually.

Anaconda Biomed's core product, the ANCD Advanced Thrombectomy System, combines innovative techniques such as the Stentriever and Aspiration methods. This system aims to minimize risks associated with traditional methods, such as distal emboli and clot fragmentation, by using a covered funnel and clot mobilizer. The company has demonstrated the efficacy of its technology through in vivo studies, with findings published in the Journal of Neurointerventional Surgery in December 2019.

The primary market for Anaconda Biomed's products includes hospitals and medical institutions specializing in stroke treatment. The business model revolves around the development, manufacturing, and sale of these specialized catheters. Revenue is generated through direct sales to healthcare providers and potential partnerships with medical device distributors.

Keywords: mechanical thrombectomy, stroke treatment, advanced catheters, medical devices, healthcare innovation, clot removal, neurointervention, patient safety, Barcelona startup, in vivo studies.